USC-UCLA Drug-Induced Liver Injury (DILI) Clinical Center.

描述（由申请人提供）：USC-UCLA药物性肝损伤临床中心（CC）申请响应RFA-DK-13-003“药物性肝损伤网络（DILIN）的延续和扩展”，希望继续与其他CC一起参与，以推进DILI的科学知识和临床评价。我们的应用程序将继续联合收割机在洛杉矶县仅有的两所医学院，使我们能够继续独特地捕捉和登记DILI病例到网络数据库由数据协调中心（DCC）监督。洛杉矶县（2011年）的930万居民是美国种族最多样化的人口组成的无与伦比的资源。我们的应用程序继续利用南加州大学和加州大学洛杉矶分校医疗中心的专业知识和人才。大量真实和患病患者的入组以及密切随访证明了我们的CC在这一多样化人群中捕获DILIN病例的能力。继续USC-UCLA DILI CC的具体目的是：1）继续招募高质量病例，收集疾病对照和急性病例进行机制研究; 2）使用遗传和血清分析详细分析HDS所致胆汁淤积性DILI; 3）与疾病对照相比，对急性DILI病例进行免疫学调查，以确定肝损伤的潜在机制; 4）在急性肝细胞病例中进行蛋白质组学研究，以确定疾病机制; 5）支持DILIN努力开发评估工具和治疗试验。

DESCRIPTION (provided by applicant): The USC-UCLA Drug-Induced Liver Injury Clinical Center (CC) application in response to RFA-DK-13-003 "Continuation and Expansion of the Drug Induced Liver Injury Network (DILIN)" hopes to continue to participate with the other CCs to advance the scientific knowledge and clinical evaluation of DILI. Our application will continue to combine the only two medical schools in Los Angeles County allowing us to continue to uniquely capture and enroll DILI cases into the Networks database supervised by the Data Coordinating Center (DCC). The 9.3 M residents of Los Angeles County (2011) are an unmatched resource composed of the most ethnically diverse population in the United States. Our application continues to utilize the expertise and talents from USC and UCLA medical centers. The enrollment of a large number of bona fide and ill patients with close follow up has demonstrated our CC's ability to capture DILIN cases in this diverse populations. The Specific Aims for the continuation of the USC-UCLA DILI CC are to: 1) Continue enrollment of high quality cases with collection of disease controls and acute cases for mechanistic studies; 2) Detailed analysis of cholestatic DILI due to HDS using genetic and serum analysis; 3) Immunological surveying of acute DILI cases compared with disease control to identify potential mechanism of liver injury; 4) Proteomic studies in acute cases of hepatocellular to identify mechanism of disease; and 5) Support of DILIN effort to develop assessment instruments and a treatment trial.